Shuai W - Search Results

1

Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.

Shuai W, Xiao H, Yang P, Zhang Y, Bu F, Wu Y, Sun Q, Wang G, Ouyang L. Shuai W, et al. J Med Chem. 2024 Apr 25;67(8):6425-6455. doi: 10.1021/acs.jmedchem.3c02392. Epub 2024 Apr 13. J Med Chem. 2024. PMID: 38613499

2

Discovery of Novel Quinoline-Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity.

Li W, Xu F, Shuai W, Sun H, Yao H, Ma C, Xu S, Yao H, Zhu Z, Yang DH, Chen ZS, Xu J. Li W, et al. Among authors: shuai w. J Med Chem. 2019 Jan 24;62(2):993-1013. doi: 10.1021/acs.jmedchem.8b01755. Epub 2018 Dec 24. J Med Chem. 2019. PMID: 30525584

3

Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities.

Zhu H, Li W, Shuai W, Liu Y, Yang L, Tan Y, Zheng T, Yao H, Xu J, Zhu Z, Yang DH, Chen ZS, Xu S. Zhu H, et al. Among authors: shuai w. Eur J Med Chem. 2021 Apr 15;216:113316. doi: 10.1016/j.ejmech.2021.113316. Epub 2021 Feb 24. Eur J Med Chem. 2021. PMID: 33676300

4

Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy.

Shuai W, Wang G, Zhang Y, Bu F, Zhang S, Miller DD, Li W, Ouyang L, Wang Y. Shuai W, et al. J Med Chem. 2021 Jun 24;64(12):7963-7990. doi: 10.1021/acs.jmedchem.1c00100. Epub 2021 Jun 8. J Med Chem. 2021. PMID: 34101463

5

Small Molecules Targeting Activated Cdc42-Associated Kinase 1 (ACK1/TNK2) for the Treatment of Cancers.

Wang A, Pei J, Shuai W, Lin C, Feng L, Wang Y, Lin F, Ouyang L, Wang G. Wang A, et al. Among authors: shuai w. J Med Chem. 2021 Nov 25;64(22):16328-16348. doi: 10.1021/acs.jmedchem.1c01030. Epub 2021 Nov 4. J Med Chem. 2021. PMID: 34735773 Review.

6

Repurposing drugs in autophagy for the treatment of cancer: From bench to bedside.

Bu F, Zhang J, Shuai W, Liu J, Sun Q, Ouyang L. Bu F, et al. Among authors: shuai w. Drug Discov Today. 2022 Jul;27(7):1815-1831. doi: 10.1016/j.drudis.2021.11.013. Epub 2021 Nov 19. Drug Discov Today. 2022. PMID: 34808390 Review.

7

Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy.

Pei J, Pan X, Wang A, Shuai W, Bu F, Tang P, Zhang S, Zhang Y, Wang G, Ouyang L. Pei J, et al. Among authors: shuai w. Chem Commun (Camb). 2021 Dec 7;57(97):13194-13197. doi: 10.1039/d1cc04661f. Chem Commun (Camb). 2021. PMID: 34816823

8

Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.

Zhu Y, Shuai W, Zhao M, Pan X, Pei J, Wu Y, Bu F, Wang A, Ouyang L, Wang G. Zhu Y, et al. Among authors: shuai w. J Med Chem. 2022 Mar 10;65(5):3758-3775. doi: 10.1021/acs.jmedchem.1c01947. Epub 2022 Feb 24. J Med Chem. 2022. PMID: 35200035

9

Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.

Tan L, Zhang J, Wang Y, Wang X, Wang Y, Zhang Z, Shuai W, Wang G, Chen J, Wang C, Ouyang L, Li W. Tan L, et al. Among authors: shuai w. J Med Chem. 2022 Apr 14;65(7):5149-5183. doi: 10.1021/acs.jmedchem.1c01714. Epub 2022 Mar 21. J Med Chem. 2022. PMID: 35311289

10

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy.

Pan X, Pei J, Wang A, Shuai W, Feng L, Bu F, Zhu Y, Zhang L, Wang G, Ouyang L. Pan X, et al. Among authors: shuai w. Acta Pharm Sin B. 2022 May;12(5):2171-2192. doi: 10.1016/j.apsb.2021.12.022. Epub 2022 Jan 4. Acta Pharm Sin B. 2022. PMID: 35646548 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209 results

Search Page

Filters